Pages that link to "Q37534923"

The following pages link to Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study (Q37534923):

Displaying 22 items.

• Clinical and molecular complexity of breast cancer metastases (Q26796326) (← links)
• Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification? (Q33699614) (← links)
• The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group (Q33854251) (← links)
• Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples. (Q34468621) (← links)
• The AURORA initiative for metastatic breast cancer (Q34499602) (← links)
• Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy? (Q35815486) (← links)
• Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. (Q36070547) (← links)
• Organ-specific isogenic metastatic breast cancer cell lines exhibit distinct Raman spectral signatures and metabolomes. (Q36266131) (← links)
• SEOM clinical guidelines in metastatic breast cancer 2015. (Q36400360) (← links)
• Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications (Q36545146) (← links)
• Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer. (Q38378354) (← links)
• Challenges in the management of advanced, ER-positive, HER2-negative breast cancer (Q38502890) (← links)
• Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs (Q38539671) (← links)
• Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent? (Q39535768) (← links)
• Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry (Q41612814) (← links)
• Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. (Q42506362) (← links)
• Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time (Q50114923) (← links)
• Discordance in Biomarker Expression in Breast Cancer After Metastasis: Single Center Experience in India (Q64072809) (← links)
• A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer (Q64085234) (← links)
• Hormone Receptors and Human Epidermal Growth Factor (HER2) Expression in Fine-Needle Aspirates from Metastatic Breast Carcinoma - Role in Patient Management (Q64094297) (← links)
• Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer (Q89690242) (← links)
• Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients (Q90471489) (← links)